1. Pink Sheet
  2. >>Geography
  3. >>International

Pricing Pressures 'Manageable' To P&G, But Threatening To Analysts

 
• By Eileen Francis

Procter & Gamble says retailer pressure for the firm to lower product pricing to compete with e-commerce and private label is a “real but manageable” problem, while an industry consultant says four megatrends are dictating product prices and changing the way consumers think about consumer health products.

Business Balance - A businessman carrying paperwork walking over a tight rope.

Pricing pressures from retailers responding to e-commerce competition is a “real but manageable” problem that Procter & Gamble Co. expects to overcome through product launches and other innovation, though analysts see it as a large and growing threat.

P&G's strategy is to differentiate its brands other than through lower prices, says P&G Chief Financial Officer Jon Moeller

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.